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Abstract
The first synthesis of dolabelide C (1), a cytotoxic marine macrolide, is reported utilizing a
phosphate tether-mediated approach. Bicyclic phosphates (S,S,SP)-5 and (R,R,RP)-5 serve as the
central building blocks for the construction of two major 1,3-anti-diol subunits in 1 through
selective cleavage pathways, regioselective olefin reduction and cross-metathesis. Overall,
phosphate-mediated processes provided copious amounts of both major subunits allowing for a
detailed RCM macrocyclization study to the 24-membered macrolactone 1.
I. Introduction: The Dolabelide Family
In 1995, the isolation and structural characterization of two new 22-membered macrolides,
dolabelides A and B, from the sea hare Dolabella auricularia was reported (Figure 1). These
compounds exhibited cytotoxicity against cervical cancer HeLa-S3 cells with IC50 values of
6.3 and 1.3 μg/mL, respectively.1 Two years later, dolabelides C and D,2 24-membered
macrolides, were isolated from the same source and were found to possess cytotoxicity
toward HeLa-S3 cells with IC50 values of 1.9, and 1.5 μg/mL, respectively. To the best of
our knowledge, the mechanism of action of these compounds remains unknown to date.
Common features among the dolabelide family are 11 stereogenic centers, 8 of which bear
oxygen, and two E-configured trisubstituted olefins. Other structural features possessed by
this family of macrolactones include 1,3-anti-diol fragments found at C7/C9 and C19/C21,
along with an accompanying 1,3-syn-diol at C9/C11 and polypropionate fragments at C1/C4
and C21/C23. The stereochemical complexity and biological profile of this class of
compounds has attracted synthetic interest from several groups3 and in 2006, the first total
synthesis of dolabelide D was reported by Leighton and coworkers.4
Dolabelide C (1) can be disconnected into C1-C14 and C15-C30 subunits, 2 and 3,
respectively (Scheme 1). The endgame for this approach is similar to Leighton's strategy
towards dolabelide D,4 employing a macrocyclization sequence to install the C14/C15
trisubstituted olefin through a late stage ring-closing metathesis (RCM) reaction.
Macrocyclization, via RCM, is preceded by Yamaguchi coupling between the C1 carboxylic
acid of the northern subunit 2 and the C23 carbinol center in the southern subunit 3. Central
to this approach are the 1,3 anti-diol motifs at C7/C9 and C19/C21, which can be assembled
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and elaborated from bicyclic phosphates (R,R,RP)-5 and (S,S,SP)-5, respectively, utilizing a
phosphate tether-mediate approach.
Results and Discussion
II. Construction of P-Chiral, Nonracemic Bicyclo[4.3.1]phosphates (R,R,RP)-5 and
(S,S,SP)-5
The enantiomeric phosphate triester building blocks (R,R,RP)-5 and (S,S,SP)-5 (Scheme 2)
were assembled via a phosphate tether, RCM desymmetrization approach5 inspired by
Burke and coworkers.6 In this method, a phosphate tether effectively serves to mediate the
tripodal coupling of anti-diol 87 with an allylic alcohol component via either a phosphoryl
monochloride or through a one-step coupling/oxidation sequence from commercially
available allyl tetraisopropylphosphorodiamidite to yield pseudo-C2-symmetric triene 9.
Desymmetrization8 by ring-closing metathesis (RCM) using Grubbs catalyst [(IMesH2)
(PCy3)(Cl)2Ru=CHPh (cat-B)]9,10,11 affords P-chiral bicyclo[4.3.1]phosphate (S,S,SP)-5 and
is based on the premise that only the terminal olefin cis to the phosphate-tethered olefin
reacts to generate 5 possessing two sterically differentiated olefins.
III. Construction of C1–C14 Subunit
We embarked upon the synthesis of the C1–C14 subunit of dolabelide beginning with an
elaborate cross methesis (CM) between bicyclic phosphate (R,R,Rp)-5 possessing a Type III
exocyclic terminal olefin and Type I olefin 10.12 As shown previously,13 CM of (R,R,Rp)-5
is high yielding with both Type I and Type II olefins in the presence of the Hoveyda-Grubbs
catalyst (cat-C).14 Various conditions for the desired CM of 10 and (R,R,Rp)-5 were probed
and it was found that employing 6 mol% Hoveyda-Grubbs catalyst at 90 °C in DCE gave the
CM adduct 4 in 72% yield (Scheme 3). This notable CM event between two complex olefins
assembles in a single operation five of the six stereocenters contained within the C1–C14
subunit of dolabelide C. Moreover, excess amounts of 10, a Type II CM partner, could be
recovered in near quantitative yield and recycled in future CM events.
Two related regioselective processes were next investigated. The first involved a
regioselective removal of the exocyclic C5–C6 olefin in the CM adduct 4 in the presence of
the C10–C11 internal olefin, which sets the stage for subsequent regioselective hydride
opening of the bicyclic system. Upon probing several hydrogenation conditions,
(Wilkinson's catalyst, Crabtree's catalyst, Pd/C) it was found that a mild diimide reduction,
generated in situ from o-nitrobenzenesulfonyl-hydrazine,15 provided the necessary
hydrogenated phosphate moiety 11 with near complete regioselectivity for the exocyclic
olefin. In comparison, other diimide conditions (tosylhydrazine, NaOAc, H2O, DCE, 90 °C)
gave drastically lower yields, likely due to bicyclic phosphate instability under basic
medium.16
Having achieved the regioselectively-hydrogenated product 11, a regioselective opening
with hydride was probed as an additional method to unmask the phosphate tether. Initial
studies focused on allylic copper hydride addition using various reagents (Stryker's reagent,
CuCN•2LiCl/PhSiH3, CeCl3•7H2O/NaBH4) (Scheme 3). Unfortunately, all conditions
probed provided only unreacted starting material or total decomposition of the reaction
mixture. Pd-catalyzed formate reductions were next investigated for generation of the
requisite terminal olefin.17 Employment of 1.5 equivalents of formic acid and 5 mol %
Pd(OAc)2 at 40 °C in DCE selectively opened phosphate 11 to provide the desired terminal
olefin in 12. Methylation of the phosphate acid intermediate showed that a highly
regioselective process was operative (>20:1 ratio of regioisomers as evident by 31P NMR
analysis). Purification provided phosphate 12 in 87% yield. The remarkable regioselectivity
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reveals another feature of the phosphate tether, whereby orthogonal orbital alignment within
11 allows for selective Pd(0)-catalyzed ionization of C12 over the C9 allylic phosphate
position. This ionization allows Pd to deliver the hydride selectively at the internal C10
position to provide the desired terminal olefin. Addition of the hydride at the terminal C12
position would afford an allylic phosphate anion that is capable of additional ionization
events with the C9 phosphate. Ultimately, the success of this reaction results in a net olefin
transposition expediting the route to the C1–C14 subunit, as well as showcasing an
additional facet of the phosphate-mediated methodology.
Upon completion of the synthesis of phosphate 12, work began toward the installation of the
C11–C14 fragment (Scheme 4). Cleavage of the phosphate was achieved using LiAlH4,
which generated a diol that was subsequently protected (PPTS, 2,2-dimethoxypropane,
CH2Cl2) to yield acetonide 13. Subsequent ozonolysis (O3, pyridine, CH2Cl2:MeOH 1:1,
Me2S) of the terminal olefin produced the requisite aldehyde, which was subjected to the
corresponding Grignard18 derived from 1-iodo-3-methyl-3-butene affording 14 in a 95%
yield. Dess-Martin periodinane (DMP, NaHCO3, CH2Cl2) oxidation of the free alcohol in
14 produced the corresponding ketone in 90% yield. Attempts to selectively reduce the
acetonide-protected ketone, using an assortment of reducing agents, failed to give any
diastereoselectivity at C11. This problem was circumvented by deprotection of the acetonide
and subsequent syn reduction utilizing the C9 alcohol. Selective removal of the acetonide
was achieved by the addition of CeCl3•7H2O and water,19 which efficiently (86% yield)
cleaved the acetonide-protecting group without loss of the primary TBS group to provide
diol 15. Final reduction of ketone 15 using Evan's conditions (Et2BOMe, NaBH4)20 afforded
triol 16 in 60% (95% brsm) with excellent diastereoselectivity (ds ≥ 20:1).
IV. First Generation Synthesis of the C15–C30 Subunit of Dolabelide C
The construction of the C15–C30 subunit of dolabelide began with the enantiomeric bicyclic
phosphate (S,S,SP)-5 possessing unique orbital symmetry of the bicyclic phosphate (Scheme
5).21 Initial studies probed the possibility of an oxidation of the exocyclic olefin of 5 in the
presence of the cyclic olefin. After testing various conditions, a chemoselective
hydroboration of (S,S,SP)-5 was achieved using 9-BBN followed by mild NaBO3 oxidation
to yield the primary alcohol. Due to the aforementioned instability of (S,S,SP)-5 to basic
hydrolysis, a mild perborate oxidation protocol developed by Burke and coworkers was
implemented. Burke has shown this protocol to be compatible with multiple acetate
protecting groups;22 optimization of this hydroboration reaction with phosphate 5 found the
reaction to be highly dependent on the amount of oxidant, equivalents of H2O, and reaction
time. Subsequent PMB ether formation using p-methoxybenzyl trichloroacetimidate
produced 17 in good yields demonstrating the acid stability of bicyclic phosphate (S,S,SP)-5.
Employing the previously reported regio- and diastereoselective cuprate addition protocol,
displacement of 17 (CuCN•2LiCl, ZnMe2, THF, -30 °C to rt) afforded the SN2′ displaced
phosphate acid exclusively (ds ≥ 20:1), which upon methylation (TMSCHN2 and MeOH)
produced cyclic phosphate ester 18 in excellent overall yield (87%). This reaction again
highlights the remarkable orbital alignment of the bicyclic phosphate system and its concave
nature, where only one of four possible products for this SN2′ cuprate reaction is generated.
Reductive cleavage, followed by sequential protection of the diol systems with TIPS and
MOM groups, and final ozonolysis of the olefin afforded aldehyde 19 in good yield.
With aldehyde 19 and vinyl iodide 20 in hand, studies aimed at a diastereoselective addition
to aldehyde 19 to set the C23 stereogenic carbinol center began (Scheme 5). Initial efforts to
generate the C23 stereocenter by lithiate additions gave predominately the undesired 1,2-
Felkin product. To overcome this problem, investigation focused on reagent-controlled,
ephedrine-based asymmetric vinylzincate additions, described by Marshall.23 Aldehyde 19
reacted with 20 under these conditions to obtain the desired 1,3-syn isomer 21 in an 11:1
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ratio of diastereomers, in 65% yield. Successful formation of 21 provided the advance
intermediate bearing the requisite stereochemistry of the C15-C30 subunit. With 21 in place,
only the installation of the C14–C15 terminal olefin was needed to complete the C15–C30
subunit of dolabelide C. MOM-protection of the C23 alcohol, DDQ removal of the PMB
ether, tosylation, and cuprate displacement all proceeded in good yield to afford the terminal
olefin 22 and complete the C15–C30 subunit of dolabelide C. Overall, a 12-step sequence to
22 from 5 was achieved, bearing the requisite stereochemistry for the C15–C30 subunit of
dolabelide C.
V. Second Generation Synthesis of the C15–C30 Subunit of Dolabelide C
A second-generation synthesis was next developed when attempts to remove the three
MOM-protecting groups from 22 proved problematic. To our dismay, all conditions tested
for cleavage of these groups in the presence of the more labile TIPS-protecting groups
provided unreacted starting material or total decomposition of the substrate (Scheme 6). The
difficulty in removing these protecting groups prompted a reevaluation of protecting groups
to access a suitable C15–C30 subunit of dolabelide. This alternative strategy coincided with
a planned installation of the C23 carbinol at the last step of the sequence to streamline the
route.
The alternative approach to the C15–C30 subunit began by employing previously
established CM/reduction methodology (Scheme 7).12a As anticipated, 5 underwent CM
with 23 in the presence of 6 mol % cat-C14 (DCE, 90 °C) providing E-configured (>20:1)
product in 82% yield. Selective reduction of the external olefin was again achieved using o-
nitrobenzenesulfonyl-hydrazine15 furnishing 24 in 75% yield.24 Compound 24 was also
synthesized through a one-pot, sequential cross-metathesis/olefin reduction protocol in 59%
overall yield utilizing the same reagents shown in Scheme 6 This yield averages to 77% per
synthetic step over the 2-step combined transformation. Regio- and diastereoselective
methyl cuprate addition into 24 and subsequent phosphate cleavage produced diol 25 in
good yield.21 Diol 25 was protected as the acetonide (PPTS, 2,2-dimethoxypropane) in 96%
yield.
The terminal olefin was next converted into primary alcohol 26 by an oxidative cleavage/
reduction sequence in good yields. TBS-protection of alcohol 26 proceeded in 86% yield
and was followed by removal of the PMB-ether to provide the corresponding primary
alcohol. Conversion of the alcohol to a terminal olefin through an iodination/elimination
sequence occurred in excellent yield over the two-step sequence. Achievement of the C14/
C15 olefin left only a deprotection/oxidation/nucleophilic addition sequence to obtain the
necessary C15–C30 subunit. TBAF removal of the TBS-protecting group to 27 and Swern
oxidation provided aldehyde 28 necessary for the addition of the C24–C30 fragment.
Despite previous success with the Marshall asymmetric zincate addition protocol,21
difficulties in reaction reproducibility and low product yields, also recently noted by
Marshall,23 prompted investigation of an alternative addition sequence. Thus, vinyl iodide
29 was converted to the lithiate with 2 equivalents of tBuLi followed by the addition of
aldehyde 28 to afford a 1:1 mixture of C23 epimers of alcohol 30 in 79% yield. The two
diastereoisomers of 30 were easily separated by column chromatography, allowing for
isolation of the correct stereoisomer of alcohol 30 as well as facile recycling (oxidation/
reduction) of the undesired diastereomer (dr = 2.7:1).25 Overall, this alternative 13-step
route to 30 from phosphate (S,S,SP)-5 provided a C15–C30 fragment ready to couple with
the C1–C14 subunit of dolabelide C.
Hanson et al. Page 4













VI. Completion of the Total Synthesis
Studies toward the completion of dolabelide C next commenced with the complete
acetylation of triol 16 to install the proper acetylation pattern for C1–C14 subunit of
dolabelide C (Scheme 8). This was accomplished by adding acetic anhydride and pyridine to
triol 16 to afford triacetate 31 in excellent yield. Deprotection of the TBS protecting group
provided alcohol 32 in 93% yield. Swern oxidation of 32 generated the desired aldehyde that
was prone to epimerization and was taken on without purification. Pinnick oxidation of the
aldehyde provided carboxylic acid 2 in 81% yield over the two-step sequence, which was
ready for coupling with the C15–C30 subunit.
Final coupling of the C1–C14 carboxylic acid 2 and the C15–C30 alcohol 30 was achieved
using Yamaguchi conditions,26 as previously described by Leighton and coworkers (Scheme
9).4 The addition of 2,4,6-trichlorobenzoyl chloride, Et3N, and DMAP at -78 °C for 21
hours avoided epimerization at C2 and yielded the desired coupled 33 in 77% yield.
Deprotection of the C27-TES protecting group was achieved with TBAF in 94% yield.
Subsequent acylation provided 34 in 98% yield. The final two protecting groups were
removed using PPTS in MeOH, followed by treatment with DDQ to provide metathesis
precursor 35 in excellent yield over two steps. Efforts to close the ring were attempted prior
to PMB ether removal and provided the desired RCM product as observed by HRMS, albeit
in poor overall conversion. As a result, subsequent investigations focused on RCM of the
deprotected triol 35. Portion-wise addition of 20 mol % of (IMesH2)(PCy3)(Cl)2Ru=CHPh
(cat-B)11 to triol 35 afforded approximately a 1:1 E/Z mixture of dolabelide C 1 and its (Z)-
isomer in a 57-60% yield.
VII. Purification Attempts and RCM/Isomerization Side Reaction
Initial attempts utilizing repeated standard normal-phase chromatography removed the Z-
isomer (higher Rf), leaving what was believed to be pure dolabelide C (1) as a single spot on
TLC. 1H NMR analysis, however, revealed impurities, which were originally presumed to
be the Z-isomer. Attempted purification using preparative reverse-phase LC-MS revealed
the major by-product, as seen by 1H NMR to be a demethylenated analog (M-14), along
with trace amounts of a constitutional isomer and two by-products resulting from formal loss
of an ethylene (M-28) as seen in the total-ion chromatogram (Figure 2). These by-products
(35a and 35b) are presumed to occur from isomerization of 35 followed by RCM, resulting
in the smaller macrocycles (Scheme 10).27 Numerous reports are consistent with this
observation28 and to the best of our knowledge; this is the first report of a detailed LC-MS
analysis of the aforementioned side reaction.
In an attempt to understand and optimize the final RCM sequence, the final metathesis
precursor was scaled-up. Both syntheses to each subunit proved to be scalable, providing
300 mg of 30 and 175 mg of 32.29 This material was carried through the same endgame
steps (Scheme 9) affording 160 mg of RCM precursor 35 to apply towards the goal of
optimizing the C14/15 E:Z ratio and minimizing the amount of deleterious side reactions
occurring in the final RCM step. For this study metathesis catalyst cat-B and three other
candidates shown in Figure 3 were screened.30
Initially, the conditions shown from Scheme 9 were reproduced (Table 1, entry 1), where
LC-MS analysis showed nearly complete conversion and a similar ratio to what was
previously observed. Screening of other catalysts by varying the phosphine or NHC-ligand
showed a significant increase of by-product formation (entries 3-5). While no significant
changes in E:Z ratio were obtained from catalyst screening, rigorous degassing and
purification of the solvent were shown to reduce deleterious side products.31
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Due to the scalability of this synthesis,32 ample material was provided for characterization,
where all NMR spectra matched with the previous reported data.2,33 In addition, sufficient
quantities of the unnatural C14/15 Z-isomer34 were generated for both NMR analysis and
collection of biological data to determine its bioactivity and potential potency against
cervical cancer.35
Conclusion
In conclusion, dolabelide C (1) and its non-natural C14–C15 Z-diastereomer were produced
and isolated from a scalable phosphate-mediated synthesis. A complex mixture was
generated in the final RCM step resulting in by-products, which arose from a net loss of CH2
and C2H4, that proved to be difficult to separate via repeated flash chromatography (8:1
CH2Cl2:acetone). Since the material produced at the end of the first synthesis of 1 was
sparse, a re-synthesis provided 175 mg of the C1–C14 subunit (32), 300 mg of the C15–C30
subunit (30) and 160 mg of RCM precursor 35. This allowed a detailed optimization study
through a screening of various metathesis catalysts, concluding with the originally
developed conditions (20 mol % cat-B, 0.5 μm, 40 °C) provided the optimum results.
Overall, 14 mg (21% yield) of pure dolabelide C and 10 mg (15% yield) of the pure Z-
isomer were produced in a 24-step longest linear sequence (LLS) from commercially
available material utilizing the (R,R,RP) antipode of 5 (sequence streamlined to a 22-step
LLS using one-pot, sequential protocols).
Experimental Section
General Methods
All reactions were carried out in oven- or flame-dried glassware, under an argon
atmosphere, using standard gastight syringes, cannulae, and septa. Stirring was achieved
with oven-dried magnetic stir bars. Et2O, THF, and CH2Cl2 were passed through a
purification system employing activated Al2O3. Et3N was eluted through basic alumina and
stored over KOH. Butyl lithium was titrated prior to use. All olefin metathesis catalysts were
obtained commercially and used without further purification. All 1H and 13C NMR spectra
were recorded in CDCl3 or C5D5N at 400 MHz or 500 MHz and 126 MHz, respectively, and
calibrated to the solvent peak. All mass spectra were obtained using electrospray ionization
(ESI) (MeOH) coupled to high-resolution mass spectrometry (HRMS). Observed rotations at
589 nm were measured using an automatic polarimeter. Infrared spectra were obtained using
a Fourier transform infrared (FTIR) spectrometer.
(4S,6R)-4-((R)-But-3-en-2-yl)-6-(5-(4-methoxybenzyloxy)pentyl)-2,2-
dimethyl-1,3-dioxane (SI-1)—Diol 25 (2.00 g, 5.95 mmol) was dissolved in CH2Cl2 (8
mL) at rt. 2,2-Dimethoxypropane (8 mL) and PPTS (150 mg, 0.595 mmol) were added
respectively and the clear solution was stirred until completion. The reaction was quenched
with saturated NaHCO3 (15 mL) and diluted with CH2Cl2. The aqueous layer was extracted
with CH2Cl2 (3 × 25 mL) and the combined organic layers were washed once with brine (30
mL), dried (Na2SO4) and concentrated under reduced pressure. Compound SI-1 was isolated
using flash chromatography (19:1 hexanes/EtOAc) as a clear oil (2.18 g, 98%); [α]D = -36.3
(c = 0.40, CH2Cl2); FTIR (neat) 2983, 2935, 2856, 1612, 1512, 819 cm -1; 1H NMR (500
MHz, CDCl3) δ 7.25 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 5.83 (ddd, J =17.4, 10.5
and 7.3 Hz, 1H), 5.03 (ddd, J = 17.5, 11.0 and 2.6 Hz, 2H), 4.43 (s, 2H), 3.80 (s, 3H), 3.74–
3.66 (m, 1H), 3.63 (ddd, J = 9.7, 6.3 and 6.3 Hz, 1H), 3.45 (t, J = 6.6 Hz, 2H), 2.18–2.26 (m,
1H), 1.71–1.64 (m, 1H), 1.63–1.53 (m, 2H), 1.55–1.35 (m, 6H), 1.32 (s, 6H), 1.30–1.24 (m,
1H), 0.98 (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 159.1, 140.9, 130.7, 129.3,
114.4, 113.7, 100.3, 72.5, 70.1, 70.0, 66.8, 55.3, 42.1, 36.3, 35.9, 29.7, 26.2, 25.3, 24.7,
24.4, 15.3; HRMS calcd for C23H36NaO4 (M+Na)+ 399.2511; found 399.2498 (ESI).
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yl)propan-1-ol (26)—Olefin SI-1 (1.50 g, 3.99 mmol) was dissolved in t-BuOH:THF:H2O
(10:2:1, 20 mL) at rt. N-Methyl morpholine N-oxide (933 mg, 7.98 mmol) and OsO4 (0.19
mL, 0.08 mmol, 4% aq) were added and the reaction was stirred for approximately 12 h until
olefin was completely consumed. The mixture was then diluted with phosphate buffer pH 7
(twice the volume of t-BuOH) and NaIO4 was added (3.41 mg, 16.0 mmol). The reaction
was stirred vigorously for approximately 2 h until the diol was completely consumed
(monitored by TLC). The reaction was quenched with solid Na2SO3 (2.0 g) and acetone was
removed under reduced pressure. The residue was partitioned with EtOAc (20 mL) and H2O
(10 mL) and the aqueous layer was extracted with EtOAc (3 × 20 mL). The collected
organics were washed once with brine (20 mL), dried (Na2SO4) and filtered. After
concentrating under reduced pressure, the crude product was purified using flash
chromatography (5:1 hexanes/EtOAc) to generate intermediate aldehyde as a yellow oil.
The resultant aldehyde was dissolved in EtOH (16 mL) and cooled to 0 °C. NaBH4 (303 mg,
7.98 mmol) was added and the reaction was slowly brought back to rt. Upon completion
(∼45 min), the solution was partitioned with 2:1, Et2O:H2O (40 mL), the aqueous layer was
extracted with Et2O (3 × 5 mL) and the organic layers were combined, washed with brine
(30 mL), dried (MgSO4), filtered and concentrated under reduced pressure. Purification with
flash chromatography (1:2 hexanes/EtOAc) afforded 26 (88% over two steps, 1.35 mg) as a
clear oil; [α]D = - 0.26 (c = 0.18, CH2Cl2); FTIR (neat) 3442, 2933, 2856, 1612, 1512, 819
cm -1; 1H NMR (500 MHz, CDCl3) δ 7.25 (d, J = 8.5 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 4.43
(s, 2H), 3.81 (s, 3H), 3.79–3.73 (m, 1H), 3.68 (ddd, J = 9.2, 6.3 and 6.3 Hz, 1H), 3.58 (d, J =
5.1 Hz, 2H), 3.43 (t, J = 6.6 Hz, 2H), 3.08 (s, 1H), 1.20–1.80 (m, 11H), 1.38 (s, 3H), 1.33 (s,
3H), 0.82 (d, J = 7.0 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 159.1, 130.8, 129.2, 113.7,
100.5, 73.1, 72.5, 70.1, 68.3, 66.6, 55.3, 40.6, 37.9, 35.8, 29.7, 26.2, 25.2, 24.6, 24.6, 12.7;
HRMS calcd for C22H36NaO5 (M+Na)+ 403.2460; found 403.2413 (ESI).
tert-Butyl((R)-2-((4S,6R)-6-(5-(4-methoxybenzyloxy)pentyl)-2,2-dimethyl-1,3-
dioxan-4-yl)propoxy)dimethylsilane (SI-2)—Alcohol 26 (1.34 mg, 3.53 mmol) was
dissolved in CH2Cl2 (23 mL) at rt. Imidazole (720 mg, 10.6 mmol), DMAP (10 mg, 0.08
mmol) and TBSCl (800 mg, 5.29 mmol) were added, respectively. The reaction was
quenched upon completion (∼90 min, monitored by TLC) with saturated NH4Cl (25 mL)
and diluted with Et2O (50 mL). The aqueous layer was extracted with Et2O (3 × 25 mL) and
the organic layers were washed with brine (25 mL). The combined organic layers were dried
(Na2SO4) and concentrated under reduced pressure. Purification with flash chromatography
(20:1 hexanes/EtOAc) afforded SI-2 (1.70 g, 97%) as a yellow oil; [α]D = -16.6 (c = 0.35,
CH2Cl2); FTIR (neat) 2933, 2856, 2881, 1247, 835 cm -1; 1H NMR (500 MHz, CDCl3) δ
7.26 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 4.24 (s, 2H), 3.80 (s, 3H), 3.74–3.66 (m,
2H), 3.56 (d, J = 4.4 Hz, 2H), 3.44 (t, J = 6.6 Hz, 2H), 1.37–1.67 (m, 11H), 1.31 (s, 6H),
0.89 (s, 9H), 0.85 (d, J = 6.8 Hz, 3H), 0.02 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 159.0,
130.7, 129.2, 113.7, 100.1, 72.5, 70.1, 67.0, 66.8, 64.1, 55.2, 40.5, 36.6, 35.9, 29.7, 26.1,
25.9, 25.3, 24.6, 24.5, 18.2, 12.2, -5.5, -5.5; HRMS calcd for C28H50NaO5Si (M+Na)+
517.3325; found 517.3334 (ESI).
5-((4R,6S)-6-((R)-1-(tert-Butyldimethylsilyloxy)propan-2-yl)-2,2-dimethyl-1,3-
dioxan-4-yl)pentan-1-ol (SI-3)—PMB ether SI-2 (1.65 g, 3.34 mmol) was dissolved in
EtOAc (16 mL) at rt. A catalytic amount of 10% Pd/C (50 mg) and NaHCO3 (280 mg, 3.34
mmol) were added sequentially and the flask was pressurized with a H2 balloon. After 10 h
the mixture was filtered through pad of Celite® and rinsed thoroughly with EtOAc. The
filtrate was concentrated under reduced pressure and purified with flash chromatography
(10:1 hexanes/EtOAc) to yield alcohol SI-3 (1.12 g, 90% yield) as a clear oil; [α]D = -0.11
(c = 0.40, CH2Cl2); FTIR (neat) 3357, 2933, 2858, 1379, 1251, 1224, 835, 775 cm-1; 1H
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NMR (500 MHz, CDCl3)36a δ 3.75–3.68 (m, 2H), 3.63 (t, J = 6.6 Hz, 2H), 3.55 (dd, J = 4.7
and 1.3 Hz, 2H), 1.70–1.38 (m, 10H), 1.33 (s, 6H), 1.28–1.22 (m, 1H), 0.89 (s, 9H), 0.84 (d,
J = 6.9 Hz, 3H), 0.04 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 100.2, 67.1, 66.8, 64.1, 63.0,
40.5, 36.6, 35.9, 32.7, 25.9 (3), 25.7, 25.3, 24.6, 24.5, 18.2, 12.2, -5.5, -5.5; HRMS calcd for
C20H42NaO4Si (M+Na)+ 397.2750, found 397.2773 (ESI).
(R)-2-((4S,6R)-2,2-Dimethyl-6-(pent-4-enyl)-1,3-dioxan-4-yl)propan-1-ol (27)—
Alcohol SI-3 (1.12 g, 2.99 mmol) was dissolved in THF (30 mL) at rt. Triphenylphosphine
(941 mg, 3.59 mmol) and imidazole (477 mg, 6.59 mmol) were added, respectively, and the
solution was cooled to 0 °C. I2 (912 mg, 3.59 mmol) was added and the reaction was stirred
for approximately 30 min (monitored by TLC). The solution was diluted with hexane and
filtered through a pad of silica, while washing with hexane, and concentrated under reduced
pressure. The crude product was taken onto the next step.
The iodo compound was dissolved in THF (35 mL) at rt followed by stepwise addition of t-
BuOK (1.0 g, 8.98 mmol). The reaction was stirred for ∼30 min. and was quenched with
H2O. The aqueous layer was extracted with EtOAc (3 × 20 mL portions) and the organic
layers were combined, washed with brine (20 mL), dried (Na2SO4), filtered and
concentrated under reduced pressure. Purification with flash chromatography (20:1 hexanes/
EtOAc) yielded the resultant terminal olefin (1.0 g, 94%) as a clear oil.
The resultant silyl ether (1.00 g, 2.81 mmol) was dissolved in THF (10 mL) and cooled to 0
°C. A solution of TBAF in THF (8.5 mL, 1.0 M in THF) was added dropwise. The reaction
was stirred at 0 °C until completion (∼45 min), quenched with saturated NH4Cl (10 mL) and
the aqueous layer was extracted with Et2O (3 × 20 mL). The organic layers were combined,
washed with brine (20 mL), dried (Na2SO4), filtered and concentrated under reduced
pressure. Purification using flash chromatography (10:1 hexanes/EtOAc) afforded 27 (670
mg, 98%) as a clear oil; [α]D = -78.6 (c = 0.50, CH2Cl2); FTIR (neat) 3446, 2983, 2935,
2879, 1379, 1224, 908 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.86–5.75 (m, 1H), 5.07–4.93
(m, 2H), 3.82–3.76 (m, 1H), 3.69 (ddd, J = 9.2, 9.2 and 6.2 Hz, 1H), 3.61–3.55 (m, 2H),
3.08 (s, 1H), 2.06 (dd, J = 14.1 and 7.1 Hz, 2H), 1.80–1.40 (m, 7H), 1.38 (s, 3H), 1.33 (s,
3H), 0.81 (d, J = 7.0 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 138.7, 114.7, 100.5, 73.0,
68.2, 66.6, 40.6, 37.8, 35.3, 33.6, 24.7, 24.6, 24.6, 12.6; HRMS calcd for C14H27O3 (M+H)+
243.1960, found 243.2895 (ESI).
(2R,3R,7R,E)-2-((4S,6R)-2,2-Dimethyl-6-(pent-4-enyl)-1,3-dioxan-4-yl)-5-
methyl-7-(triethylsilyloxy)dec-4-en-3-ol (30)—A solution of oxalyl chloride (0.158
mL, 1.86 mmol) in CH2Cl2 (4.8 mL) was cooled to -78 °C and DMSO (0.220 mL, 3.01
mmol) was added slowly by syringe (gas evolution). After stirring for 10 min, a solution of
alcohol 27 (300 mg, 1.24 mmol) in CH2Cl2 (3.0 mL) was added by cannula and rinsed with
CH2Cl2 (2 × 0.5 mL). The cloudy mixture was stirred at -78 °C for 15 min at which time
Et3N (0.700 mL, 4.96 mmol) was added dropwise. The reaction mixture was stirred for 1 h
at -78 °C, quenched cold with saturated NaHCO3 (5 mL) and allowed to warm to rt. After
diluting with CH2Cl2, the layers were separated and the aqueous layer was re-extracted with
CH2Cl2 (3 × 12 mL). The organic layer was dried (Na2SO4), filtered through a silica plug
and rinsed (3 × 25 mL) with a EtOAc/CH2Cl2(1:1). The filtrate was concentrated under
reduced pressure to give aldehyde 28 as a yellow oil. The crude aldehyde was taken
immediately to the next reaction without further purification.
To a solution of the vinyl iodide 29 (1.01 mg, 2.75 mmol) in Et2O (10 mL) at −78 °C was
added t-BuLi (1.7 M in pentane, 3.40 mL, 5.75 mmol), and the reaction was immediately
warmed to 0 °C for 25 min. The reaction was recooled to -78 °C, and the aldehyde 28 was
slowly added via syringe in Et2O (2.5 mL, 0.60 mL rinse). After 1 h, the reaction was
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quenched at -78 °C with saturated NH4Cl, warmed to rt, and the layers were separated. The
aqueous layer was extracted with Et2O (2 × 10 mL), and the combined organic layers
washed with brine (15 mL), dried (Na2SO4), filtered and concentrated under reduced
pressure. Flash chromatography (10:1 hexanes/EtOAc) afforded a 1:1 mixture of 1,3-syn and
1,3-anti 30 (ratio determined by 1H NMR analysis of crude reaction mixture, 464 mg,
combined yield of diastereomers 77% over two steps).
Oxidation/Reduction Sequence: The 1,3-anti diastereomer (65 mg, 0.135 mmol) of 30 was
dissolved in CH2Cl2 (2.6 mL) at rt. Dess-Martin periodinane (115 mg, 0.270 mmol) was
added to the stirring solution, where upon completion (monitored by TLC), the reaction was
diluted with Et2O (5 mL). The organic layer was washed with saturated NaHCO3 (2 × 5 mL)
and dried (Na2SO4). After filtration, the solvent was removed under reduced pressure and
the residual oil was purified through a short plug of SiO2 (1:1 hexanes/EtOAc) providing a
clear oil (40 mg, 85%).
The ketone (6 mg, 0.0125 mmol) was dissolved in MeOH and cooled to 0 °C. NaBH4 (11
mg, 0.035 mmol) was added slowly and the mixture was stirred until the ketone was
completely consumed (monitored by TLC). The mixture was partitioned with H2O:Et2O
(1:1, 10 mL) and the resultant aqueous layer was extracted with Et2O (3 × 5 mL). The
collected organic layers were washed with brine (5 mL) and dried (Na2SO4). The epimeric
ratio of the crude material was determined by 1H NMR analysis after filtration and removal
of solvent under reduced pressure, (∼2.7:1). Flash chromatography (5:1 hexanes/EtOAc)
provided both isomers (4 mg, 89%) as a clear oil; [α]D = -8.1 (c = 1.3, CH2Cl2); FTIR (neat)
3456, 2954, 2935, 2875, 1458, 1379, 1224, 908 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.82
(dddd, J = 16.9, 10.1, 6.7 and 6.7 Hz, 1H), 5.16 (d, J = 9.1 Hz, 1H), 5.01 (ddd, J = 17.1, 3.4
and 1.5 Hz, 1H), 4.95 (d, J = 10.2 Hz, 1H), 4.27 (t, J = 8.7 Hz, 1H), 3.99 (s, 1H), 3.84–3.74
(m, 3H), 2.27 (dd, J =14.1 and 4.3 Hz, 1H), 2.16 (dd, J = 8.7 and 3.0 Hz, 1H), 2.06 (q, J =
7.0 Hz, 2H), 1.70 (s, 3H), 1.41 (s, 3H), 1.35 (s, 3H), 1.72–1.20 (m, 11H), 0.96 (t, J = 8.2 Hz,
9H), 0.88 (t, J = 7.3 Hz, 3H), 0.71 (d, J = 6.9 Hz, 3H), 0.59 (q, J = 8.2 Hz, 6H); 13C NMR
(126 MHz, CDCl3) δ 138.6, 136.0, 128.8, 114.6, 100.6, 72.9, 72.4, 70.7, 66.6, 48.5, 44.1,
38.7, 38.0, 35.2, 33.6, 24.7, 24.6, 24.5, 18.4, 17.3, 14.2, 11.6, 7.0, 5.0; HRMS calcd for
C28H54NaO4Si (M+Na)+ 505.3689; found 505.3674 (ESI).
(5S,7R,9S,12R,13S,14R)-15-(tert-Butyldimethylsilyloxy)-13-(4-
methoxybenzyloxy)-2,12,14-trimethylpentadec-1-ene-5,7,9-triyl triacetate (31)
—To a solution of triol 16 (132 mg, 0.232 mmol) in CH2Cl2 (3.3 mL) was added DMAP (3
mg, 0.023 mmol), pyridine (0.750 mL, 9.30 mmol), and acetic anhydride (0.45 mL, 4.65
mmol). The reaction was stirred until disappearance of starting material at rt (∼2 h). The
reaction was diluted with EtOAc (5 mL), quenched with saturated NH4Cl (5 mL), and the
aqueous layer was re-extracted with EtOAc (3 × 10 mL). The organic layer was washed with
brine (10 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. Flash
chromatography (5:1 hexanes/EtOAc) provided 31 (151 mg, 94%) as a clear oil; [α]D =
+12.4 (c = 0.50, CH2Cl2); FTIR (neat) 2956, 2929, 2883, 2856, 1739, 1514, 1461, 1247
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 4.97
(dddd, J = 9.5, 6.2, 6.2 and 3.1 Hz, 1H), 4.89 (m, 2H), 4.71 (s, 1H), 4.66 (s, 1H), 4.53 (d, J =
10.9 Hz, 1H), 4.46 (d, J = 10.9 Hz, 1H), 3.80 (s, 3H), 3.71 (dd, J = 9.7 and 5.3 Hz, 1H), 3.63
(dd, J = 9.7 and 3.3 Hz, 1H), 3.25 (dd, J = 8.7 and 2.4 Hz, 1H), 2.07–1.99 (m, 2H), 2.05 (s,
3H), 2.03 (s, 3H), 1.99 (s, 3H), 1.92 (dddd, J = 18.7, 10.2, 4.4 and 4.4 Hz, 1H), 1.84–1.68
(m, 5H), 1.71 (s, 3H), 1.64–1.54 (m, 4H), 1.46–1.38 (m, 1H), 1.34–1.22 (m, 1H), 0.92 (s,
9H), 0.90 (d, J = 2.3 Hz, 3H), 0.88 (d, J = 2.3 Hz, 3H), 0.06 (s, 6H); 13C NMR (126 MHz,
CDCl3) δ 170.8, 170.7, 170.6, 159.1, 144.9, 131.7, 129.3, 113.9, 110.5, 83.3, 74.6, 70.9,
70.3, 67.5, 65.1, 55.4, 39.2, 38.7, 38.6, 35.4, 33.5, 33.1, 32.3, 30.5, 26.1, 22.6, 21.3, 21.3,
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21.2, 18.5, 14.8, 13.6, -5.2, -5.2; HRMS calcd for C38H64NaO9Si (M+Na)+ 715.4217; found
715.4213 (ESI).
(5S,7R,9S,12R,13S,14R)-15-Hydroxy-13-(4-methoxybenzyloxy)-2,12,14-
trimethylpentadec-1-ene-5,7,9-triyl triacetate (32)—To a solution of 31 (150 mg,
0.216 mmol) in THF (2.3 mL) was added TBAF (0.70 mL, 1.0 M in THF). The reaction was
stirred until disappearance of starting material at rt (∼3 h). The reaction was diluted with
EtOAc (3 mL), quenched with saturated NH4Cl (5 mL), and the aqueous layer was re-
extracted with EtOAc (2 × 5 mL). The organic layer was dried (Na2SO4), filtered and
concentrated under reduced pressure. Flash chromatography (2:1 hexanes/EtOAc) provided
32 (118 mg, 94%) as a clear oil; [α]D = +13.1 (c = 2.4, CH2Cl2); FTIR (neat) 3502, 3072,
2964, 2935, 2875, 1737, 1514, 1454, 1245 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.28 (d, J =
8.5 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 4.98 (dddd, J = 9.6, 6.3, 6.3 and 3.3 Hz, 1H), 4.99–
4.85 (m, 2H), 4.73 (s, 1H), 4.67 (s, 1H), 4.58 (d, J = 10.6 Hz, 1H), 4.51 (d, J = 10.6 Hz, 1H),
3.81 (s, 3H), 3.62–3.67 (m, 2H), 3.25 (dd, J = 7.6, 3.3 Hz, 1H), 2.71 (s, 1H), 2.07–1.99 (m,
2H), 2.06 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 1.95–1.86 (m, 2H) 1.84–1.68 (m, 6H), 1.72 (s,
3H), 1.64–1.56 (m, 2H), 1.54–1.44 (m, 1H), 1.34–1.22 (m, 1H), 0.96 (d, J = 6.9 Hz, 3H),
0.94 (d, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 170.7, 170.6, 170.5, 159.3, 144.7,
130.4, 129.4 (2), 113.9 (2), 110.4, 87.6, 74.8, 70.6, 70.0, 67.3, 66.5, 55.3, 39.0, 38.4, 37.7,
36.1, 33.3, 32.8, 32.2, 30.0, 22.4, 21.2, 21.1, 21.1, 15.4, 14.3; HRMS calcd for C32H50NaO9
(M+Na)+ 601.3353; found 601.3354 (ESI).
(2S,3S,4R,7S,9R,11S)-7,9,11-Triacetoxy-3-(4-methoxybenzyloxy)-2,4,14-
trimethylpentadec-14-enoic acid (2)—A solution of oxalyl chloride (0.046 mL, 0.539
mmol) in CH2Cl2 (1.67 mL) was cooled to -78 °C and DMSO (0.077 mL, 1.08 mmol) was
added slowly by syringe (gas evolution). After stirring for 10 min a solution of alcohol 32
(125 mg, 0.21 mmol) in CH2Cl2 (2.0 mL) was added by cannula and rinsed with CH2Cl2 (2
× 0.2 mL). The cloudy mixture was stirred at -78 °C for 15 min at which time Et3N (0.18
mL, 1.29 mmol) was added dropwise. The reaction mixture was stirred for 2 h at -78 °C.
The reaction was quenched at -78 °C with saturated NaHCO3 (3 mL) and allowed to warm
to rt. The reaction was diluted with CH2Cl2, and the layers were separated. The aqueous
layer was re-extracted with CH2Cl2 (3 × 5 mL). The organic layer was dried (Na2SO4),
filtered and concentrated under reduced pressure to give aldehyde as a yellow oil. The crude
aldehyde was taken immediately to the next reaction with further purification.
To a solution of crude aldehyde was added t-butanol (4.5 mL) and 2-methyl-2-butene (1.5
mL). A solution of NaClO2 (390 mg, 4.30 mmol) and sodium dihydrogen phosphate (470
mg, 3.01 mmol) in H2O (2.0 mL) was prepared and added to the reaction mixture by
syringe. The yellow solution was stirred vigorously for 2 h at rt, diluted with Et2O (15 mL)
and poured into H2O (9 mL). The layers were separated and the aqueous phase was
extracted with Et2O (3 × 10 mL). The combine organic layers were dried (Na2SO4), filtered
and concentrated under reduced pressure. Flash chromatography (1:1 hexanes:EtOAc)
provided 2 (104 mg, 81% over two steps) as a clear oil; [α]D = +8.13 (c = 0.16, CH2Cl2);
FTIR (neat) 3251, 3076, 2964, 2923, 2854, 1737, 1714, 1512, 1454, 1245 cm-1; 1H NMR
(400 MHz, CDCl3) δ 7.24 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 5.10–4.85 (m, 3H),
4.73 (s, 1H), 4.67 (s, 1H), 4.56 (d, J = 10.7 Hz, 1H), 4.50 (d, J = 10.6 Hz, 1H), 3.79 (s, 3H),
3.57 (dd, J = 7.2 and 3.5 Hz, 1H), 2.78 (dddd, J = 14.33, 7.1, 7.1 and 7.1 Hz, 1H), 2.07–1.99
(m, 2H), 2.06 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 1.95–1.86 (m, 2H), 1.84–1.64 (m, 5H), 1.72
(s, 3H), 1.64–1.40 (m, 3H), 1.39–1.20 (m, 2H), 1.17 (d, J = 7.1 Hz, 3H), 0.93 (d, J = 6.7 Hz,
3H); 13C NMR (126 MHz, CDCl3) δ 179.9, 170.8, 170.7, 170.5, 159.4, 144.7, 130.0, 129.5
(2), 113.9 (2), 110.3, 84.2, 74.4, 70.8, 69.9, 67.3, 55.3, 42.3, 39.0, 38.1, 35.6, 33.3, 32.5,
32.3, 28.9, 22.4, 21.2, 21.1, 21.1, 14.7, 14.4; HRMS calcd for C32H48NaO10 (M+Na)+
615.3145; found 615.3131 (ESI).
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triacetate (33)—To a solution of alcohol 30 (77 mg, 0.159 mmol), carboxylic acid 2 (106
mg, 0.175 mmol), and DMAP (975 mg, 7.98 mmol) in toluene (32 mL) at -78 °C was added
Et3N (0.5 mL, 3.61 mmol) dropwise followed by the slow addition of 2,4,6-trichlorobenzoyl
chloride (0.56 mL, 3.58 mmol), which caused the white solution to thicken. The mixture was
stirred for 21 h at -78 °C ensuring that the bath temperature did not rise above -65 °C. The
reaction flask was then moved to a dry ice/CH3CN bath and stirred for 2.5 h maintaining the
temperature between -30 °C to -42 °C. At the end of the 2.5 h the solution was slowly
allowed to warm to rt in the bath over 1 h. The flask was placed in an ice bath for 2 h while
being stirred. The reaction was quenched by the addition of sataturated NaHCO3 (15 mL).
The layers were separated and the aqueous layer was back extracted with Et2O (25 mL). The
combined organic layers were dried (Na2SO4), filtered, and concentrated under reduce
pressure. Purification by flash chromatography (5:1 hexanes/EtOAc) provided ester 33 (130
mg, 77%) as a colorless oil; [α]D +3.63 (c = 0.28, CH2Cl2); FTIR (neat) 3076, 2954, 2935,
2875, 1739, 1515, 1442, 1244 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.19 (d, J = 8.7 Hz, 2H),
6.83 (d, J = 8.7 Hz, 2H), 5.82 (dddd, J = 17.0, 10.2, 6.8 and 6.8 Hz, 1H), 5.68 (dd, J = 9.9
and 5.7 Hz, 1H), 5.17 (d, J = 9.8 Hz, 1H), 5.02 (ddd, J = 17.1, 3.2 and 1.6 Hz, 1H), 5.00–
4.93 (m, 3H), 4.94–4.85 (m, 2H), 4.74 (s, 1H), 4.67 (s, 1H), 4.51 (d, J = 10.8 Hz, 1H), 4.34
(d, J = 10.8 Hz, 1H), 3.79 (s, 3H), 3.70–3.80 (m, 2H), 3.69–3.60 (m, 3H), 2.69 (dt, J = 14.2
and 7.1 Hz, 1H), 2.20–1.89 (m, 8H), 2.06 (s, 3H), 2.04 (s, 3H), 2.00 (s, 3H), 1.80–1.20 (m,
18H), 1.76 (s, 3H), 1.73 (s, 3H), 1.34 (s, 3H), 1.29 (s, 3H), 1.08 (d, J = 7.1 Hz, 3H), 0.96 (t,
J = 7.9 Hz, 9H), 0.93–0.84 (m, 9H) 0.58 (q, J = 7.9 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ
175.3, 170.6, 170.6, 170.5, 158.9, 144.7, 139.6, 138.8, 131.2, 129.0, 122.7, 114.6, 113.6,
110.3, 100.1, 83.1, 73.9, 71.4, 70.7, 70.2, 70.0, 67.3, 67.1, 66.5, 55.2, 53.5, 48.8, 43.5, 42.1,
39.1, 38.5, 38.5, 35.4, 34.7, 33.7, 33.3, 32.1, 30.3, 29.9, 29.7, 24.9, 24.9, 24.8, 22.4, 21.2,
21.1, 21.1, 18.3, 17.6, 15.3, 14.8, 14.2, 13.2, 9.8, 7.0 (3), 5.0 (3); HRMS calcd for




triacetate (SI-4)—Ester 33 (75 mg, 0.071 mmol) was dissolved in THF (1 mL) and cooled
to 0 °C. A solution of TBAF in THF (0.214 mL, 1.0 M in THF) was added dropwise. The
reaction stirred at 0 °C until completion (approximately 45 min). The reaction was quenched
with saturatred NH4Cl and the aqueous layer was extracted with EtOAc (3 × 10 mL). The
organic layers were combined, washed with brine (5 mL), dried (Na2SO4), filtered and
concentrated under reduced pressure. Purification by flash chromatography (2:1 hexanes/
EtOAc) afforded SI-4 (63 mg, 94%) as a clear; [α]D = -11.4 (c = 1.0, CHCl3); 1H NMR (400
MHz, CDCl3) δ 7.22 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 5.81 (dddd, J = 17.0,
10.2, 6.7 and 6.7 Hz, 1H), 5.64 (dd, J = 9.9 and 5.2 Hz, 1H), 5.20 (d, J = 9.6 Hz, 1H), 5.01
(ddd, J = 17.1, 3.4 and 1.6 Hz, 1H), 5.00–4.93 (m, 2H), 4.93–4.85 (m, 2H), 4.72 (s, 1H),
4.67 (s, 1H), 4.53 (d, J = 10.7 Hz, 1H), 4.38 (d, J = 10.7 Hz, 1H), 3.79 (s, 3H), 3.76–3.69
(m, 1H), 3.66–3.59 (m, 1H), 3.60–3.54 (m, 1H), 3.53 (dd, J = 8.4, 3.0 Hz, 1H), 2.70 (dt, J =
15.2 and 7.2 Hz, 1H), 2.15–1.87 (m, 8H), 2.06 (s, 3H), 2.04 (s, 3H), 2.00 (s, 3H), 1.80–1.20
(m, 21H), 1.76 (s, 3H), 1.73 (s, 3H), 1.33 (s, 3H), 1.28 (s, 3H), 1.10 (d, J = 7.1 Hz, 3H),
0.93–0.84 (m, 9H); 13C NMR (126 MHz, CDCl3) δ 175.1, 170.7, 170.6, 170.5, 158.9, 144.7,
139.6, 138.7, 131.2, 128.8, 123.1, 114.6, 113.5, 110.3, 100.2, 83.7, 73.8, 71.8, 70.7, 70.0,
68.4, 67.3, 66.4, 55.2, 53.5, 48.1, 43.4, 42.1, 39.2, 39.1, 38.5, 36.3, 35.4, 35.1, 33.7, 33.3,
32.8, 32.2, 29.8, 29.7, 24.8, 24.6, 22.4, 21.2, 21.1, 21.0, 18.9, 17.5, 14.8, 14.2, 13.6, 9.9;
HRMS calcd for C54H86NaO13 (M+Na)+ 965.5966; found 965.5897 (ESI).
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triacetate (34)—To a solution of SI-4 (58 mg, 0.062 mmol) in CH2Cl2 (3.0 mL) was
added DMAP (1 crystal), pyridine (0.2 mL, 2.46 mmol) and acetic anhydride (0.117 mL,
1.23 mmol). The reaction was stirred at rt until disappearance of starting material (∼2 h).
The reaction was diluted with EtOAc (3 mL), quenched with saturated NH4Cl (3 mL) and
the aqueous layer was re-extracted with EtOAc (3 × 5 mL). The organic layer was washed
with brine (5 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. Flash
chromatography (1.5:1 hexanes/EtOAc) provided 34 (60 mg, 98%) as a clear oil; [α]D =
+2.2 (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.18 (d, J = 8.6 Hz, 2H), 6.83 (d, J =
8.6 Hz, 2H), 5.80 (dddd, J = 16.9, 10.2, 6.7 and 6.7 Hz, 1H), 5.67 (dd, J = 9.9 and 5.6 Hz,
1H), 5.16 (d, J = 9.7 Hz, 1H), 5.00 (ddd, J = 17.1, 3.4 and 1.6 Hz, 1H), 5.00–4.92 (m, 3H),
4.92–4.84 (m, 2H), 4.73 (s, 1H), 4.66 (s, 1H), 4.50 (d, J = 10.9 Hz, 1H), 4.35 (d, J = 10.9
Hz, 1H), 3.79 (s, 3H), 3.75–3.68 (m, 1H), 3.62–3.55 (m, 2H), 2.68 (dt, J = 16.0 and 6.9 Hz,
1H), 2.15–1.87 (m, 8H), 2.06 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.80–1.20 (m,
20H), 1.77 (s, 3H), 1.73 (s, 3H), 1.33 (s, 3H), 1.27 (s, 3H), 1.06 (d, J = 7.1 Hz, 3H), 0.93–
0.84 (m, 9H); 13C NMR (126 MHz, CDCl3) δ 175.1, 170.6, 170.6, 170.6, 170.5, 158.9,
144.7, 138.7, 138.6, 131.3, 128.8, 122.5, 114.6, 113.5, 110.3, 100.2, 83.2, 73.8, 72.1, 71.2,
70.7, 70.0, 67.3, 66.4, 55.2, 53.5, 44.2, 42.1, 39.2, 39.1, 35.9, 35.4, 33.7, 33.3, 32.2, 31.9,
31.6, 29.9, 24.8, 24.8, 22.7, 21.3, 21.2, 21.1, 21.0, 18.4, 17.8, 14.7, 14.2, 14.2, 14.0, 13.2,




triacetate (SI-5)—To a solution of tetraacetate 34 (60 mg, 0.061 mmol) in MeOH (6 mL)
was added PPTS (2.5 mg, 0.03 mmol). The reaction was stirred until disappearance of
starting material at rt (∼ 4 h). The reaction was diluted with EtOAc, quenched with saturated
NaHCO3 and the aqueous layer was re-extracted with EtOAc (3 × 10 mL). The organic layer
was washed with brine (10 mL), dried (Na2SO4), filtered and concentrated under reduced
pressure. Flash chromatography (1.5:1 hexanes/EtOAc) provided SI-5 (47 mg, 82%) as a
clear oil; [α]D = +8.97 (c = 1.7, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.21 (d, J = 8.3 Hz,
2H), 6.85 (d, J = 8.4 Hz, 2H), 5.82 (dddd, J = 15.8, 12.1, 5.4 and 5.4 Hz, 1H), 5.69 (dd, J =
9.7 and 6.0 Hz, 1H), 5.18 (d, J = 9.8 Hz, 1H), 5.05–4.85 (m, 6H), 4.73 (s, 1H), 4.67 (s, 1H),
4.51 (d, J = 10.9 Hz, 1H), 4.34 (d, J = 11.0 Hz, 1H), 3.92–3.86 (m, 1H), 3.80 (s, 3H), 3.71
(m, 1H), 3.58 (dd, J = 8.4, 2.0 Hz, 1H), 2.73 (dddd, J = 14.2, 6.8, 6.8 and 6.8 Hz, 1H), 2.50–
1.19 (m, 28H), 2.07 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.82 (s, 3H), 1.72 (s, 3H), 1.09 (d, J =
7.0 Hz, 3H), 0.89 (t, J = 7.3 Hz, 3H), 0.86–0.81 (m, 9H); 13C NMR (126 MHz, CDCl3) δ
175.1, 170.7, 170.6, 170.6, 170.5, 158.9, 144.7, 138.7, 138.6, 131.1, 128.4, 123.4, 114.7,
113.7, 110.3, 83.5, 73.8, 73.5, 72.5, 70.7, 70.1, 68.8, 67.3, 60.4, 55.2, 44.3, 43.4, 43.0, 39.5,
39.1, 38.5, 37.1, 36.3, 34.9, 33.7, 33.3, 32.2, 31.6, 29.8, 25.1, 22.7, 21.3, 21.2, 21.1, 21.1,




trimethyl-15-oxopentadec-1-ene-5,7,9-triyl triacetate (35)—Ester SI-5 (105 mg,
0.112 mmol) was taken up in CH2Cl2 (5.0 mL) followed by the addition of pH = 7 buffer
solution (5.0 mL) and DDQ (51 mg, 0.224 mmol) at rt. Upon completion (∼0.5 h, monitored
by TLC), CH2Cl2 (13 mL) was added followed by saturated NaHCO3 (1 mL). The layers
were separated, and the aqueous layer extracted with CH2Cl2 (3 × 10 mL). The combined
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organic layers were washed with brine (10 mL), dried (anhydrous Na2SO4), filtered, and
concentrated under reduced pressure. Flash chromatography (2:1 hexanes/EtOAc) afforded
35 (89 mg, 97%) as a clear oil. [α]D = +4.4 (c = 0.50, CHCl3); 1H NMR (400 MHz, CDCl3)
δ 5.79 (dddd, J = 17.0, 10.2, 6.7 and 6.7 Hz, 1H), 5.19 (dd, J = 9.7 and 9.5 Hz, 1H), 5.07–
4.87 (m, 6H), 4.73 (s, 1H), 4.66 (s, 1H), 4.15–4.09 (m, 2H), 3.96–3.89 (m, 1H), 3.71 (dd, J =
9.9 and 1.2 Hz, 1H), 2.54 (dddd, J = 14.1, 7.0, 7.0 and 7.0 Hz, 1H), 2.17–1.19 (m, 28H),
2.07 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.82 (s, 3H), 1.72 (s, 3H), 1.08 (d, J = 7.0 Hz, 3H),
0.89 (t, J = 7.3 Hz, 3H), 0.86–0.81 (m, 9H); 13C NMR (126 MHz, CDCl3) δ 174.0, 172.4,
170.8, 170.8, 170.6, 144.6, 138.7, 138.0, 125.3, 114.6, 110.4, 72.6, 72.6, 72.4, 71.9, 70.7,
68.1, 67.1, 66.9, 45.3, 44.2, 42.7, 39.0, 37.6, 37.3, 36.9, 36.0, 33.7, 33.6, 33.3, 32.3, 31.5,
29.0, 25.3, 22.4, 21.4, 21.3, 21.2, 21.1, 18.5, 17.8, 13.9, 13.6, 12.5, 9.5; HRMS calcd for
C45H76NaO13 (M+Na)+ 847.5184; found 847.5183 (ESI).
Dolabelide C (1)—To a refluxing solution of ester 23 (70 mg, 0.085 mmol) in degassed
CH2Cl2 (175 mL) was added Grubbs II catalyst (8.0 mg, 0.0085 mmol). The reaction was
refluxed 2 h with the addition of more catalyst (4.0 mg, 0.00425 μmol) after 2 h. A third
portion of catalyst (4.0 mg, 0.00425) was had after 2 more hours; the reaction was refluxed
for 6 hours (monitored by TLC and LC-MS). The solution was cooled to rt and concentrated
under reduced pressure. The resultant residue was purified via flash chromatography
through two sequential columns (8:1 CH2Cl2/acetone) and (5:1 pentane/EtOAc) afforded 1,
(14.0 mg, 21% yield) as an analytically pure sample and its C14–C15 Z-configured
diastereomer (10.0 mg, 15% yield) (vide infra); [α]D = +2.9 (c = 0.63, CHCl3); 1H NMR
(500 MHz, pyridine-d5)36b δ 6.10-5.90 (br m, 1H), 5.70 (t, J = 9.3 Hz, 1H), 5.67 (s, 1H),
5.40 (d, J = 9.5 Hz, 1H), 5.38–5.31 (m, 2H), 5.30–5.23 (m, 2H), 5.16–5.10 (m, 1H), 4.88–
4.82 (m, 1H), 4.37–4.32 (m, 1H), 4.03 (br d, J = 9.1 Hz, 1H), 2.93–2.85 (m, 1H), 2.52–2.48
(m, 1H), 2.32 (dd, J = 14.0 and 7.9 Hz, 1H), 2.28 (dd, J = 13.9 and 5.4 Hz, 1H), 2.21–2.15
(m, 1H), 2.11–2.00 (m, 6H), 2.08 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.05 (s, 3H), 1.98 (s,
3H), 1.96–1.92 (m, 2H), 1.90–1.80 (m, 4H), 1.79–1.58 (m, 7H), 1.59 (s, 3H), 1.53–1.49 (m,
3H), 1.32–1.28 (m, 2H), 1.19 (d, J = 7.3 Hz, 3H), 1.16 (d, J = 7.0 Hz, 3H), 0.90 (d, J = 6.6
Hz, 3H), 0.84 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, pyridine-d5) δ 173.9, 170.6, 170.5,
170.4, 170.3, 136.7, 132.6, 127.3, 127.2, 74.3, 73.5, 71.8, 69.9, 69.9, 68.0, 67.9, 67.3, 46.4,
44.5, 43.7, 38.8, 38.5, 38.0, 37.2, 36.3, 35.2, 34.1, 31.8, 31.6, 29.3, 28.0, 27.0, 21.1, 21.0,
20.9, 20.9, 18.8, 17.6, 15.2, 14.0, 13.8, 12.6, 11.0; 1H NMR (500 MHz, CDCl3) δ 5.35 (t, J
= 9.1 Hz, 1H), 5.10–5.05 (m, 2H), 5.04–5.00 (m, 1H), 4.98–4.92 (m, 1H), 4.88–4.82 (m,
2H), 4.08 (s, 1H), 3.93 (s, 1H), 3.57 (s, 1H), 3.24 (s, 1H), 2.60–2.54 (m, 1H), 2.54–2.47 (m,
1H), 2.25 (dd, J = 13.8 and 7.1 Hz, 1H), 2.21 (dd, J = 14.1 and 5.7 Hz, 1H), 2.07 (s, 3H),
2.03 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.90–1.83 (m, 2H), 1.81 (s, 3H), 1.78–1.64 (m, 3H),
1.64–1.62 (m, 4H), 1.58 (s, 3H), 1.56 (m, 9H), 1.43–1.27 (m, 5H), 1.25 (s, 3H), 1.23–1.20
(m, 1H), 1.07 (d, J = 7.1 Hz, 3H), 0.89 (t, J = 7.3 Hz, 3H), 0.84 (m, 6H); 13C NMR (126
MHz, CDCl3) δ 173.8, 171.2, 171.0, 170.7, 170.4, 137.9, 133.1, 126.1, 125.0, 74.6, 73.1,
72.2, 69.8, 69.2, 68.7, 68.1, 67.7, 45.1, 44.3, 42.7, 39.1, 36.8, 36.1, 35.1, 34.6, 31.9, 31.7,
29.7, 28.3, 26.7, 25.0, 21.2, 21.2, 21.2, 21.1, 18.5, 17.7, 15.2, 13.9, 13.6, 12.6, 10.6; HRMS
calcd for C43H72NaO13 (M+Na)+ 819.4871; found 819.4858 (ESI).
Non-Natural C14-C15 Z-Isomer of 1—[α]D = +10.0 (c = 0.30, CHCl3); 1H NMR (500
MHz, pyridine-d5)36c δ 6.28 (br s, 1H), 6.20–6.05 (br m, 1H), 5.85 (t, J = 9.4 Hz, 1H), 5.51
(d, J = 8.8 Hz, 1H), 5.48–5.40 (m, 2H), 5.38–5.29 (m, 2H), 5.27–5.18 (m, 1H), 4.88–4.84
(m, 1H), 4.53–4.46 (m, 1H), 4.14 (br d, J = 7.4 Hz, 1H), 3.03–2.97 (m, 1H), 2.64–2.56 (m,
1H), 2.43 (dd, J = 7.5, 13.8 Hz, 1H), 2.37 (dd, J = 5.3, 13.1 Hz, 1H), 2.34–2.23 (m, 3H),
2.22–2.19 (m, 1H), 2.18–2.14 (m, 12H), 2.13–2.12 (m, 2 H), 2.08 (s, 3 H), 2.06–2.02 (m, 1
H), 2.02–2.00 (m, 1 H), 1.99–1.95 (m, 2 H), 1.95–1.91 (m, 1 H), 1.91–1.86 (m, 2 H), 1.84–
1.78 (m, 2 H), 1.77 (s, 3 H), 1.75–1.66 (m, 3 H), 1.64–1.58 (m, 3 H); 1.49–1.31 (m, 4 H),
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1.29 (d, J = 7.0 Hz, 6 H), 1.04 (d, J = 6.6 Hz, 3 H), 0.94 (t, J = 7.3 Hz, 3 H); 13C NMR (126
MHz, pyridine-d5) δ 174.2, 170.9, 170.9, 170.7, 170.6, 137.2, 134.3, 127.3, 126.9, 75.2,
73.6, 72.2, 71.8, 70.1, 68.3, 68.2, 68.1, 46.6, 44.8, 44.3, 39.9, 39.2, 39.0, 37.6, 36.7, 34.4,
32.8, 32.0, 29.3, 28.4, 27.9, 27.5, 23.3, 21.4, 21.4, 21.3, 21.3, 19.1, 17.9, 14.3, 14.3, 13.0,
11.4; 1H NMR (500 MHz, CDCl3)36d δ 5.13–5.07 (m, 2H), 5.03–4.97 (m, 3H), 4.96–4.91
(m, 1H), 4.90–4.85 (m, 1H), 4.27 (s, 1H), 4.05–4.01 (m, 1H), 3.68 (d, J = 9.7 Hz, 1H), 2.54
(tt, J = 7.0 Hz, 1H), 2.31–2.20 (m, 4H), 2.13–2.11 (m, 1H), 2.11–2.08 (m, 1H), 2.06–2.04
(m, 2H), 2.04–2.03 (m, 6H), 2.02 (s, 3H), 2.01 (s, 3H), 2.00–1.97 (m, 1H), 1.97–1.95 (m,
1H), 1.82 (s, 3H), 1.81–1.76 (m, 2H), 1.76–1.74 (m, 1H), 1.74–1.71 (m, 1H), 1.66 (s, 3H),
1.61 (s, 1H), 1.58–1.56 (m, 1H), 1.48–1.46 (m, 2H), 1.45–1.43 (m, 2H), 1.42–1.39 (m, 2H),
1.38–1.25 (m, 6H), 1.01 (d, J = 7.0 Hz, 3H), 0.89 (t, J = 7.3 Hz, 3H), 0.82 (d, J = 7.0 Hz,
3H), 0.79 (d, J = 6.7 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 173.6, 171.6, 171.3, 170.7,
170.4, 137.6, 133.9, 125.9, 125.8, 74.0, 72.8, 72.3, 71.3, 70.8, 68.0, 67.0, 66.6, 45.7, 44.1,
42.9, 38.0, 37.4, 37.0, 35.9, 34.9, 33.6, 32.2, 31.1, 28.2, 26.7, 25.9, 22.8, 21.4, 21.2, 21.2,
21.2, 21.2, 18.5, 17.8, 13.9, 13.4, 11.5, 9.36; HRMS calcd for C43H72NaO13 (M+Na)+
819.4871; found 819.4877 (ESI).
HPLC-MS Analysis of 1: HPLC data was collected using the following gradient over 35
min:
Time (min) A% (99:1 H2O:MeCN) B% (99:1 MeCN: H2O) Flow Rate (mL/min)
0.00 95.0 5.0 1.000
1.00 40.0 60.0 1.000
31.00 30.0 70.0 1.000
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35. Purification of each isomer was achieved using 2-3 consecutive runs on normal phase flash
chromatography (see supporting information).
36. (a) Spectrum integrated to 41 total H, where the unassigned H was presumed to be an O-H peak
undergoing H-D exchange; (b) Spectrum integrated to 71 total H, where the unassigned H was
presumed to be an O-H peak undergoing H-D exchange. Only the O-H peaks did not match
exactly to the reported data; (c) Spectrum integrated to 71 total H, where the unassigned H was
presumed to be an O-H peak undergoing H-D exchange; (d) Spectrum integrated to 69 total H,
where the unassigned H's were presumed to be O-H peaks undergoing H-D exchange.
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The dolabelide family, isolated from Dollabella auricularia.
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LC-MS analysis of mixture from final RCM.
Hanson et al. Page 19














Metathesis Catalysts Screened on Final RCM Step.
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Scheme 1. Retrosynthesis of Dolabelide C
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Scheme 2. Tether-Mediated Desymmetrization of C2-Symmetric 1,3-anti-Diol 8a
aReagents and Conditions: (a) Allyl tetraisopropylphosphorodiamidite, 1-H-tetrazole,
MeCN, 2 h, rt, then m-CBPA, 1 h, 64%; (b) cat-B, CH2Cl2, 85-90%.
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Scheme 3. Phosphate-Mediated Sequence for Assembly of the C1–C14 Subunita
aReagents and Conditions: (a) cat-C (6 mol %), DCE, 90 °C, 72%; (b) o-
NO2C6H5SO2NHNH2, Et3N, CH2Cl2, 72%; (c) Pd(OAc)2 (5 mol %), HCO2H, Et3N, DCE,
40 °C, then MeOH, TMSCHN2, 87%. Abbreviations: DCE = dichloroethane.
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Scheme 4. Synthesis of C1–C14 Carbon Frameworka
aReagents and conditions: (a) LiAlH4, Et2O, 75%; (b) PPTS, 2,2-DMP, CH2Cl2, 96%; (c)
O3, pyridine, 1:1 MeOH:CH2Cl2, -78 °C, then Me2S, 72%; (d) 1-Iodo-3-methyl-butene, Mg,
Et2O, -78 °C, 95%; (e) Dess-Martin periodinane, NaHCO3, CH2Cl2, 90%; (f) CeCl3•7H2O,
H2O/MeCN (1:7), 87%; (g) Et2BOMe, NaBH4, THF:MeOH 4:1, -78 °C, ds ≥ 20:1, 60%
(95% brsm).
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Scheme 5. First Generation Synthesis of the C15–C30 Subunita
aReagents and conditions: (a) 9-BBN, then H2O, NaBO3•4H2O, 80%; (b) p-
OMeC6H4OCH2OC=NH(CCl3), PPTS, CH2Cl2, 89%; (c) 1. CuCN•2LiCl, Me2Zn, THF,
-30 °C to rt; 2. TMSCHN2, MeOH, 87%; (d) LiAlH4, Et2O, 0 °C, 96%; (e) TIPSCl,
imidazole, DMAP, CH2Cl2, 86%; (f) MOMCl, iPr2NEt, CH2Cl2, 91%; (g) O3, pyridine, -78
°C, Me2S, 75%; (h) t-BuLi, ZnBr2, 20, then n-BuLi, (R,S,)-NME, then 19, 65%, 11:1 dr; (i)
MOMCl, iPr2NEt, DCE, 82%; (j) DDQ, pH 7 buffer, CH2Cl2, 92%; (k) TsCl, DABCO,
CH2Cl2, 90%; (l) allylMgBr, CuI, -20 °C to 0 °C, 89%. Abbreviations: 9-BBN = 9-
borabicyclo(3.3.1)nonane; TMS = trimethylsilyl; TIP = triisopropylsilyl; MOM =
methoxymethyl; DMAP = 4-(dimethylamino)pyridine; NME = N-methylephedrine; DDQ =
2,3-dichloro-5,6-dicyanobenzoquinone; Ts = tosyl; DABCO = 1,4-
diazabicyclo(2.2.2)octane.
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Scheme 6. MOM-deprotection Conditions
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Scheme 7. Second Generation Synthesis of C15–C30 Subunita
aReagents and conditions: (a) cat-C (6 mol %), 23, DCE, 90 °C, 82%; (b) o-
NO2C6H5SO2NHNH2, Et3N, CH2Cl2, 75%; (c) 1. CuCN•2LiCl, Me2Zn, THF, -30 °C to rt;
2. TMSCHN2, MeOH, 91%; (d) LiAlH4, Et2O, 0 °C, 92%; (e) 2,2-DMP, PPTS, CH2Cl2,
96%; (f) OsO4, NMO, t-BuOH/THF/ H2O, then NaIO4, Phosphate Buffer pH 7, then
NaBH4, EtOH, 0 °C, 81%; (g) TBSCl, pyridine, 95%; (h) H2, Pd/C, EtOAc, NaHCO3, 90%;
(i) Ph3P, I2, imidazole, then t-BuOK, THF, 94%; (j) TBAF, THF, 98%; (k) (COCl)2,
DMSO, Et3N, CH2Cl2, -78 °C to rt; (l) t-BuLi, Et2O, 29, -78 °C to 0 °C, 30 min, 28, -78 °C,
∼1:1 syn:anti, 79% over 2 steps; (m) Dess-Martin, CH2Cl2, 85% n) NaBH4, MeOH, 0 °C,
89%, ∼2.7:1 syn:anti. Abbreviations: DMP = dimethoxypropane; PPTS = pyridinium p-
toluenesulfonate; NMO = N-methylmorpholine N-oxide; TBS = tert-butyldimethylsilyl;
TBAF = tetra-n-butylammonium fluoride.
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Scheme 8. Generation of ready-to-couple C1–C14 Subunita
aReagents and conditions: (a) Ac2O, DMAP, pyridine, 95%; (b) TBAF, THF, 93%; (c)
(COCl)2, DMSO, Et3N, CH2Cl2; (d) NaClO2, 2-methyl-2-butene, H3PO4, 81% over 2 steps.
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Scheme 9. Completion of Dolabelide C (1)a
aReagents and conditions: (a) 2,4,6-trichlorobenzoyl chloride, DMAP, Et3N, toluene, 77%;
(b) TBAF, 94%; (c) Ac2O, pyridine, DMAP, 98%; (d) PPTS, 83%; (e) DDQ, Phosphate
Buffer pH = 7, CH2Cl2, 95%; (f) cat-B (20 mol %), CH2Cl2 (0.5 mM), 57%, E:Z = ∼1:1.
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Scheme 10. Possible Isomerization Pathways from Metathesis Step
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Table 1
Catalyst Screening of Final RCM.
Entry Catalyst Conversion E:Za E:Z: By-Pdtsa
1 cat-B >99% 1:1 1:1:0.17
2 cat-Bb 87% 1.2:1 1.2:1:0.26
3 cat-D 100% 1:1 1:1:0.80
4 cat-E 100% 1:1.1 1:1.1:0.45
5 cat-F 87% 1.2:1 1.2:1:0.61
a
Ratios determined through peak area integration from LC-MS analysis of crude mixtures.
b
Purified newly purchased catalyst through SiO2 plug in 10:1 hexanes:EtOAc.
c
All reactions were run with stepwise addition of 20 mol % catalyst over 6 h at 40 °C in 0.5 μM CH2Cl2.
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